REGENXBIO Dividend
Dividend criteria checks 0/6
REGENXBIO does not have a record of paying a dividend.
Key information
n/a
Dividend yield
n/a
Payout ratio
| Industry average yield | 2.9% |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | n/a |
| Earnings per share | -US$5.37 |
| Dividend yield forecast in 3Y | 0% |
Recent dividend updates
No updates
Recent updates
REGENXBIO Inc. (NASDAQ:RGNX) Not Doing Enough For Some Investors As Its Shares Slump 26%
Apr 25
Regenxbio: DMD Program Lends Additional Credibility To NAV Technology Platform
Mar 11Analysts Just Slashed Their REGENXBIO Inc. (NASDAQ:RGNX) EPS Numbers
Mar 07Improved Revenues Required Before REGENXBIO Inc. (NASDAQ:RGNX) Stock's 75% Jump Looks Justified
Mar 05Earnings Update: REGENXBIO Inc. (NASDAQ:RGNX) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts
Mar 02Regenxbio: Robust Data, Decent Cash, Never Ending Trials, Buying At Dips
Jan 19There's No Escaping REGENXBIO Inc.'s (NASDAQ:RGNX) Muted Revenues
Dec 21We Think REGENXBIO (NASDAQ:RGNX) Needs To Drive Business Growth Carefully
Nov 09Will REGENXBIO (NASDAQ:RGNX) Spend Its Cash Wisely?
Aug 08REGENXBIO Inc. (NASDAQ:RGNX) Analysts Just Trimmed Their Revenue Forecasts By 12%
May 11Here's Why We're Watching REGENXBIO's (NASDAQ:RGNX) Cash Burn Situation
May 08Analysts Are More Bearish On REGENXBIO Inc. (NASDAQ:RGNX) Than They Used To Be
Mar 05REGENXBIO says additional phase 2 data bolsters RGX-314 for wet macular degeneration
Oct 03Regenxbio: A Transformative Year
Sep 15Regenxbio: Updates To Thesis, Gene Therapy Pioneer Moving To Late-Stage Development
Aug 29Regenxbio to seek FDA's accelerated approval for Hunter Syndrome treatment, shares rise 8%
Aug 03Regenxbio: Patience And Regular Homework Are Keys
Jul 12REGENXBIO Inc. (NASDAQ:RGNX) Analysts Just Slashed This Year's Estimates
Jun 27The Strong Earnings Posted By REGENXBIO (NASDAQ:RGNX) Are A Good Indication Of The Strength Of The Business
May 12Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Insufficient data to determine if RGNX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if RGNX's dividend payments have been increasing.
Dividend Yield vs Market
| REGENXBIO Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (RGNX) | n/a |
| Market Bottom 25% (US) | 1.5% |
| Market Top 25% (US) | 4.7% |
| Industry Average (Biotechs) | 2.9% |
| Analyst forecast in 3 Years (RGNX) | 0% |
Notable Dividend: Unable to evaluate RGNX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate RGNX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate RGNX's payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as RGNX has not reported any payouts.